WallStSmart
GBIO

Generation Bio Co

NASDAQ: GBIO · HEALTHCARE · BIOTECHNOLOGY

$5.34
+0.00% today

Updated 2026-02-09

Market cap
$35.98M
P/E ratio
P/S ratio
2.36x
EPS (TTM)
$-9.37
Dividend yield
52W range
$3 – $7
Volume
0.1M

Generation Bio Co (GBIO) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2018201920202021202220232024
Operating cash flow$-28.12M$-40.35M$-70.14M$-91.82M$-102.45M$-52.74M$-88.56M
Capital expenditures$3.02M$19.99M$5.52M$5.96M$8.80M$7.40M$2.40M
Depreciation
Stock-based comp$3.49M$4.21M$8.41M$17.86M$24.45M$24.34M$14.61M
Free cash flow$-31.14M$-60.33M$-75.66M$-97.78M$-111.25M$-60.14M$-90.96M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash$47.76M$315.90M$-281.97M

Frequently asked questions

What is Generation Bio Co's revenue?

Generation Bio Co's trailing twelve-month revenue is $15.27M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is GBIO?

In its most recent fiscal year, GBIO ran a gross margin of 100.00%, an operating margin of -715.82%, and a net margin of -661.91%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does GBIO generate?

GBIO produced $-90.96M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.